tirzepatide and cardiovascular outcomes outperforms dulaglutide in study | Janinne Ortega-Montiel, MD-ScD posted on the topic Tirzepatide cardiovascular event risk assessment:

Do I need a consultation before starting wellness treatment

Comment: A commenter recommended that CMS consider including arrhythmia detection in the ASM heart failure measure set, noting that the measure would help address a key, often undetected driver of heart failure morbidity and cost, and align with HHS's Make America Healthy Again initiative

NHS website

Be aware that these carry a small risk of euglycaemic diabetic ketoacidosis DPP-4 inhibitors (e.g., sitagliptin, linagliptin), which are generally well tolerated but less effective for weight reduction Metformin , if not already prescribed, remains the first-line oral agent for type 2 diabetes, though it can also cause gastrointestinal upset Insulin therapy , which may be necessary if oral agents and GLP-1 agonists are not tolerated or insufficient, though this carries a risk of hypoglycaemia When discussing alternatives with your GP, consider bringing up: The severity and duration of your symptoms Any dietary or lifestyle modifications you have already tried Your treatment priorities (e.g., cardiovascular protection, convenience) Other medical conditions or medications that may influence treatment choice NICE guidance (NG28) recommends individualised treatment approaches for type 2 diabetes, taking into account patient preferences, comorbidities, and tolerability

Heres some helpful information so you can actually give melatonin a fair try before deciding whether or not it can help you: 1

However, any patient reporting new symptoms of thyroid dysfunctionsuch as unexplained swelling at the base of the neck, sudden appetite changes, or severe fatigueshould contact their provider immediately for thyroid testing and evaluation